Nuvation Bio Stock Fundamentals
| NUVB Stock | USD 2.80 0.15 5.08% |
Nuvation Bio fundamentals help investors to digest information that contributes to Nuvation Bio's financial success or failures. It also enables traders to predict the movement of Nuvation Stock. The fundamental analysis module provides a way to measure Nuvation Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nuvation Bio stock.
At present, Nuvation Bio's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Depreciation And Amortization is expected to grow to about 261.8 K, whereas EBIT is forecasted to decline to (104.8 M). Nuvation | Select Account or Indicator |
Nuvation Bio Company Return On Equity Analysis
Nuvation Bio's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Nuvation Bio Return On Equity | -0.88 |
Most of Nuvation Bio's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nuvation Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Nuvation Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Nuvation Bio has a Return On Equity of -0.883. This is 96.32% lower than that of the Biotechnology sector and 97.58% lower than that of the Health Care industry. The return on equity for all United States stocks is 184.84% higher than that of the company.
Nuvation Bio Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Nuvation Bio's current stock value. Our valuation model uses many indicators to compare Nuvation Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nuvation Bio competition to find correlations between indicators driving Nuvation Bio's intrinsic value. More Info.Nuvation Bio is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Nuvation Bio's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Nuvation Bio's earnings, one of the primary drivers of an investment's value.Nuvation Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nuvation Bio's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nuvation Bio could also be used in its relative valuation, which is a method of valuing Nuvation Bio by comparing valuation metrics of similar companies.Nuvation Bio is currently under evaluation in return on equity category among its peers.
Nuvation Bio ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Nuvation Bio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Nuvation Bio's managers, analysts, and investors.Environmental | Governance | Social |
Nuvation Fundamentals
| Return On Equity | -0.88 | ||||
| Return On Asset | -0.54 | ||||
| Operating Margin | (327.79) % | ||||
| Current Valuation | 425.11 M | ||||
| Shares Outstanding | 333.78 M | ||||
| Shares Owned By Insiders | 27.01 % | ||||
| Shares Owned By Institutions | 44.62 % | ||||
| Number Of Shares Shorted | 17.96 M | ||||
| Price To Book | 3.84 X | ||||
| Price To Sales | 653.23 X | ||||
| EBITDA | (99.6 M) | ||||
| Net Income | (75.8 M) | ||||
| Cash And Equivalents | 703.8 M | ||||
| Cash Per Share | 3.22 X | ||||
| Total Debt | 4.01 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 33.58 X | ||||
| Book Value Per Share | 1.03 X | ||||
| Cash Flow From Operations | (68 M) | ||||
| Short Ratio | 12.83 X | ||||
| Earnings Per Share | (2.22) X | ||||
| Target Price | 6.75 | ||||
| Number Of Employees | 167 | ||||
| Beta | 1.38 | ||||
| Market Capitalization | 937.38 M | ||||
| Total Asset | 621.48 M | ||||
| Retained Earnings | (342.8 M) | ||||
| Working Capital | 602.46 M | ||||
| Net Asset | 621.48 M |
About Nuvation Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nuvation Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nuvation Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nuvation Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Cost Of Revenue | 222 K | 323.7 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Nuvation Stock
When determining whether Nuvation Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Nuvation Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nuvation Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nuvation Bio Stock:Check out Nuvation Bio Piotroski F Score and Nuvation Bio Altman Z Score analysis. For information on how to trade Nuvation Stock refer to our How to Trade Nuvation Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nuvation Bio. If investors know Nuvation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nuvation Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.22) | Revenue Per Share 0.006 | Return On Assets (0.54) | Return On Equity (0.88) |
The market value of Nuvation Bio is measured differently than its book value, which is the value of Nuvation that is recorded on the company's balance sheet. Investors also form their own opinion of Nuvation Bio's value that differs from its market value or its book value, called intrinsic value, which is Nuvation Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nuvation Bio's market value can be influenced by many factors that don't directly affect Nuvation Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nuvation Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nuvation Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nuvation Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.